Condition (MeSH)
Craniosynostoses
ClinicalTrials.gov lists 81 trials for Craniosynostoses or a narrower condition beneath it. Incyte Corporation has the most among industry and government lead sponsors, with 7.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
49 of the 81 trials are tagged with Craniosynostoses itself; the rest are tagged with a narrower condition beneath it.
When did Craniosynostoses trials start? (22)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 12
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 4 |
| 2024 | 5 |
| 2023 | 4 |
| 2022 | 5 |
| 2021 | 4 |
| 2020 | 12 |
| 2019 | 8 |
| 2018 | 2 |
| 2017 | 6 |
Showing 10 of 22 earlier years.
No forecast is made for this condition: it averages 4.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 35 months across 44 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Craniosynostoses trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 9 |
| Phase 1/2 | 3 |
| Phase 2 | 15 |
| Phase 3 | 2 |
| Phase 4 | 2 |
| Not applicable | 20 |
| Observational | 30 |
How many Craniosynostoses trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 7 |
| Recruiting | 11 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 5 |
| Completed | 33 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Craniosynostoses trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Incyte Corporation | 7 |
| National Human Genome Research Institute (NHGRI) | 4 |
| Janssen Research & Development, LLC | 3 |
| Basilea Pharmaceutica | 2 |
| Eisai Co., Ltd. | 2 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Craniosynostoses? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Infigratinib | 3 |
| E7090 | 3 |
| Rogaratinib | 2 |
| PEMBROLIZUMAB | 2 |
| Aminocaproic Acid | 2 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Pemigatinib Pill | 6 |
| acid tranexamic | 3 |
| Gemcitabine/Gemzar | 2 |
| Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles | 1 |
| Derazantinib 200 mg once daily + atezolizumab 1200 mg | 1 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Craniosynostoses trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Disease progression | 35 | 3 |
| Abdominal pain | 27 | 5 |
| Urinary tract infection | 27 | 4 |
| Acute kidney injury | 20 | 4 |
| General physical health deterioration | 20 | 3 |
Showing 5 of 10 adverse events.
Which publications cover Craniosynostoses? (110)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Comparing effectiveness of conservative policy to craniofacial surgery in children with metopic synostosis: protocol for an observational cohort study on clinical outcomes, psychosocial well-being and costs in a Dutch academic hospital. | BMJ open | 2025 | Yes |
| Postoperative coagulopathy among otherwise healthy pediatric patients undergoing open craniosynostosis repair: a retrospective study. | European journal of pediatrics | 2023 | Yes |
| Importance of tranexamic acid in pediatric monosutural craniosynostosis surgery. | Journal of neurosurgery. Pediatrics | 2022 | Yes |
| Cerebral Blood Flow of the Frontal Lobe in Untreated Children with Trigonocephaly versus Healthy Controls: An Arterial Spin Labeling Study. | Plastic and reconstructive surgery | 2022 | Yes |
| Updated Guideline on Treatment and Management of Craniosynostosis. | The Journal of craniofacial surgery | 2021 | Yes |
Showing 5 of 110 publications.
Prevalence (15)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Craniosynostosis | Prevalence at birth | 1-5 / 10 000 | United States | US | Unspecified |
| Craniosynostosis | Prevalence at birth | 1-5 / 10 000 | United States | US | Exact |
| Craniosynostosis | Prevalence at birth | 1-5 / 10 000 | United States | US | Exact |
| Craniosynostosis | Prevalence at birth | 1-5 / 10 000 | Europe | Not stated | Exact |
| Craniosynostosis | Prevalence at birth | 1-5 / 10 000 | Australia | Not stated | Unspecified |
Showing 5 of 15 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Craniosynostosis | 1531 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Craniosynostosis | 1531 | Exact | Orphadata Science knowledge files, Product 1 |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.